Live Symposium
Cancer drug discovery continues to evolve with advances in molecular biology, novel biological models, high-throughput tools, and data-driven approaches. As researchers unravel the complexities of tumor biology and resistance mechanisms, new opportunities are emerging for the development of more effective therapeutics and diagnostics. In this two-day symposium, experts will share cutting-edge technologies and translational approaches that are shaping the future of cancer treatment.
Topics to be covered:
- Overcoming therapeutic resistance through patient-derived models and tumor organoids
- Precision targeting and functional genomics approaches, including CRISPR and proteomics
- Emerging technologies for cancer diagnosis and biomarker discovery
- Integrating AI and data-driven methods to accelerate small molecule development
- Innovative assay platforms and tools to support drug discovery workflows
Tuesday October 28th - Wednesday October 29th, 2025
11:00 AM - 4:00 PM Eastern Time
This symposium will be available to view live and on demand.

Heidi Haikala, PhD
Principal Investigator, Assistant Professor
University of Helsinki & Tampere University

Ethan Shelkey, PhD
R&D Scientist
Lonza

Thomas Kislinger, PhD
Professor
University of Toronto

Yong Zeng, PhD
Associate Professor
University of Florida

Christophe Deben, PhD
Professor
University of Antwerp

Derek Sokolowski, MSL
Product Manager, Cell Culture
PHC Corporation of North America

Kiel Peck, PhD
Director, Scientific Operations
Crown Bioscience
.png)
Mats Ljungman, PhD
Professor
University of Michigan Medical School
.png)
Edward Han, PhD
Product Manager
Bruker Cellular Analysis

Michal Harel, PhD
VP of Translational Medicine
OncoHost

Kirsteen (Kirsty) Maclean, PhD
Principal Scientist, Pharma Services
NeoGenomics

Min Xue, PhD
Associate Professor
Icahn School of Medicine at Mount Sinai

Sean Porazinski, PhD
Application Science Lead
Inventia Life Science
Executive Sponsor

Premium Sponsors




Standard Sponsors


